Income StatementBalance SheetCash FlowSegments
Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals Income Statement

Revenue, expenses, and profitability over time

Regeneron Pharmaceuticals generated $14.9B in trailing twelve-month revenue, up 0.1% year-over-year. Net income was $4.4B with a 29.65% net margin. Diluted EPS is $40.96, which grew 0.0% year-over-year. Based on the Q1 2026 filing.

Total Revenue (TTM)$14.9BOperating Income (TTM)$3.6BNet Income (TTM)$4.4BEps Diluted (TTM)$40.96
Latest FilingQ1 2026
Report Date2026-04-29
Market Cap$66.0B
P/E Ratio14.92
ROE14.55%

Earnings Per Share

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Basic earnings per share$8.55$7.58$13.24$14.09$8.16$6.99
Diluted earnings per share$8.12$7.27$12.81$13.62$7.78$6.75
Weighted-average shares, basic—106.7M105.1M103.6M—104M
Weighted-average shares, diluted—111.2M108.6M107.2M—107.7M

Other Income & Expense

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Other Charges$0.0$322.0M$442.8M$755.8M$176.0M$201.2M
Interest expense$10.5M$8.7M$3.6M$19.3M$12.2M$12.9M
Other income (expense), net$0.0$313.3M$439.2M$736.5M$163.8M$188.3M

Income Before Tax

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Income before income taxes$958.1M$905.0M$1.5B$1.8B$1.0B$831.2M

Tax

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Income tax expense$40.4M$96.3M$127.1M$303.3M$199.1M$104.0M

Net Income

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Net income$917.7M$808.7M$1.4B$1.5B$844.6M$727.2M

Operating Expenses

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Acquired in-process research and development$13.8M$12.3M$10.0M$83.1M$18.7M$101.9M
Research and development$1.4B$1.3B$1.4B$1.5B$1.6B$1.5B
Selling, general and administrative$792.2M$633.0M$634.2M$657.8M$775.0M$647.7M
Total operating expenses$2.8B$2.4B$2.6B$2.7B$3.0B$3.0B

Operating Income

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Operating income$990.2M$591.7M$1.1B$1.0B$879.9M$642.9M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Comprehensive Income (Loss), Net of Tax, Attributable to Parent$849.6M$845.7M$1.4B$1.5B$853.1M$661.6M
Net unrealized gains (losses) on securities still held—$38.1M$22.1M$15.7M$7.1M-$65.8M

Revenue

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Total revenue$3.8B$3.0B$3.7B$3.8B$3.9B$3.6B